Hikma Pharmaceuticals reported solid global growth in its injectables business on Thursday, with strong customer demand for its product portfolio in North America, although some challenges meant it expected revenue and operating margin growth at the lower end of guidance. Hikma said it was committed to expanding its injectables business through substantial investments. In the branded sector, Hikma saw strong demand, particularly for medicines used to treat chronic illnesses in key MENA markets. Finally, in the generics business, Hikma said it was having a successful year due to favourable market dynamics in its base business and stronger-than-expected revenue from its authorised generic of sodium oxybate. As a result, Hikma said it now expected 2023 revenue to fall within the range of $920m to $940m, with a core operating margin of around 20%.

Source: The North Africa Journal November 02, 2023 09:00 UTC